Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises Medlive Technology's US$540 million Hong Kong IPO

  • en
  • zh
  • Language options

19 July 2021

Clifford Chance advises Medlive Technology's US$540 million Hong Kong IPO

Leading international law firm Clifford Chance has advised the underwriters Goldman Sachs, Haitong International Capital, and China International Capital Corporation (CICC) on the US$540 million initial public offering of Medlive Technology Co., Ltd on the Main Board of Hong Kong Stock Exchange. Goldman Sachs and Haitong International Capital also act as joint sponsors of the IPO.

Established in 2013, Medlive Technology is one of the largest online platforms for medical professionals (physicians, pharmaceutical and medical device companies, hospitals) and patients in China. Medlive Technology provides its participants with a wide spectrum of solutions, including digital healthcare marketing services, patient recruitment service for clinical trials, real-world studies (RWS) solutions, latest clinical references, AI-enabled patient management services and electronic data capture (EDC) system for automated data collection and management.

Partners Christine Xu and Fang Liu co-led the deal with support from senior associates Gehuan Liu, Queenie Tong, Qingqing Bu, Emma Bao and trainee Yumeng Fan.

Christine said, "The successful IPO of Medlive Technology indicates that the demand for initial public offerings in Hong Kong will continue to grow especially in the healthcare and TMT sectors. We are honoured to have supported Medlive Technology in achieving a historic milestone in its development."

The firm's Greater China IPO practice regularly advises on IPOs in the healthcare sector, including Ping An Good Doctor, SciClone Pharmaceuticals and Hygeia Healthcare. The firm has also advised on the IPOs of early-stage biotech companies such as Zylox-Tonbridge Medical Technology, Harbour BioMed and Ascentage Pharma.